Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 (Ivosidenib) + Azacitidine in Untreated IDH1-Mutant AML
DRKS00022839Phase 3Terminated
- Sponsor
- Agios Pharmaceuticals
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Ivosidenib + azacitidine with Placebo + azacitidine (2 arms). Started Sep 2020; status: terminated.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00022839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00022839.